Tuesday, December 17, 2019 8:39 PM EDT
BiondVax's Josh Phillipson spoke with Edison TV about the company's M-001 Universal Flu Vaccine pivotal Phase 3 clinical trial
BiondVax Pharmaceuticals (Nasdaq: BVXV) is a clinical biopharmaceutical company developing a universal flu vaccine, known as M-001. M-001 is currently undergoing a pivotal, clinical efficacy, Phase III trial in about 12,400 participants, the results of which are expected by the end of 2020.
M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains. In six completed clinical trials to date, the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains.
Disclaimer: Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and ...
more
Disclaimer: Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. This document may contain materials from third parties, which are supplied by companies that are not affiliated with Edison Investment Research. Edison Investment Research has not been involved in the preparation, adoption or editing of such third-party materials and does not explicitly or implicitly endorse or approve such content. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of publication and is subject to change without notice. While based on sources believed reliable, we do not represent this material as accurate or complete. Any views or opinions expressed may not reflect those of the firm as a whole. Edison Investment Research does not engage in investment banking, market making or asset management activities of any securities. The material has not been prepared in accordance with the legal requirements designed to promote the independence or objectivity of investment research.
less
How did you like this article? Let us know so we can better customize your reading experience.